STF Management LP Lowers Holdings in AstraZeneca PLC (NASDAQ:AZN)

STF Management LP reduced its position in AstraZeneca PLC (NASDAQ:AZN) by 8.3% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 8,486 shares of the company’s stock after selling 768 shares during the period. STF Management LP’s holdings in AstraZeneca were worth $661,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in AZN. McClarren Financial Advisors Inc. boosted its stake in shares of AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after purchasing an additional 247 shares in the last quarter. GHP Investment Advisors Inc. bought a new stake in AstraZeneca during the 2nd quarter valued at $26,000. Capital Performance Advisors LLP bought a new position in shares of AstraZeneca in the 3rd quarter worth $28,000. Pathway Financial Advisers LLC purchased a new stake in shares of AstraZeneca during the 1st quarter worth $29,000. Finally, CANADA LIFE ASSURANCE Co boosted its position in AstraZeneca by 40.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after purchasing an additional 146 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on AZN shares. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Finally, TD Cowen boosted their target price on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $89.75.

AstraZeneca Price Performance

Shares of AZN opened at $64.13 on Friday. The firm has a market capitalization of $198.83 billion, a PE ratio of 30.68, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The company’s fifty day moving average price is $73.69 and its 200-day moving average price is $77.86. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The business had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company’s revenue was up 18.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.87 earnings per share. On average, equities research analysts predict that AstraZeneca PLC will post 4.1 EPS for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.